AC Immune Announces CEO Retirement, Interim Leadership Appointments, and 2026 Clinical Outlook

AC Immune SA announced that Dr. Andrea Pfeifer will retire as Chief Executive Officer effective at the Annual General Meeting (AGM) on June 11, 2026, following a 23-year tenure. The Board has appointed current Chair, Dr. Martin Zügel, to serve as Interim CEO while a permanent successor is sought. To maintain independent oversight during this transition, Dr. Monika Bütler has been appointed as Lead Independent Director. Additionally, Dr. Carl June was appointed to the Audit & Finance Committee to meet regulatory requirements. The filing also highlights clinical progress and upcoming milestones. The company expects full 104-week data from Part 1 of the Phase 2 VacSYn trial for ACI-7104 (Parkinson’s disease) in H2 2026, with plans to launch a larger proof-of-concept trial thereafter. Interim 12-month results for ACI-24.060 in Alzheimer's are anticipated in H1 2026. Furthermore, SAD/MAD results for the NLRP3 inhibitor ACI-19764 are expected in H2 2026. The company reported a cash runway extending into Q4 2027 following a strategic restructuring.